We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Blueprint Medicines Corp (BPMC) USD0.001

Sell:$95.04 Buy:$95.13 Change: $1.60 (1.71%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $1.60 (1.71%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $1.60 (1.71%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Contact details

45 Sidney Street
United States
+1 (617) 3747580

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$5.84 billion
Shares in issue:
61.23 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Jeffrey Albers
    Chairman of the Board
  • Kathryn Haviland
    President, Chief Executive Officer, Director
  • Michael Landsittel
    Chief Financial Officer
  • Fouad Namouni
    President - Research and Development
  • Christina Rossi
    Chief Operating Officer
  • Debra Durso-Bumpus
    Chief People Officer
  • Christopher Murray
    Executive Vice President, Chief Technical Operations and Quality Officer
  • Ariel Hurley
    Senior Vice President - Finance, Principal Accounting Officer
  • Percy Carter
    Chief Scientific Officer
  • Tracey Mccain
    Chief Legal and Compliance Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.